Han C H, Yin C H, Chen J S, Chen Y S, Chu C H, Chuang W C, Hung H C
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Taiwan.
Acta Endocrinol (Buchar). 2024 Apr-Jun;20(2):193-200. doi: 10.4183/aeb.2024.193. Epub 2025 Jan 18.
Understanding factors delaying recovery in thyrotoxicosis patients is crucial for optimizing treatment plan.
This study aimed to identify predictive factors for the delayed thyroid function recovery in thyrotoxicosis patients.
The study is a retrospective review of medical records of adult thyrotoxicosis patients diagnosed at Kaohsiung Veterans General Hospital, Taiwan, from January 2014 to December 2021. The duration of follow-up for the main outcome was at least 18 months.
Patients newly diagnosed with thyrotoxicosis who were age > 18 years old, had a TSH level <0.1 μIU/mL, received CBZ or PTU treatment, and demonstrated a subsequent TSH increase to above 0.4 μIU/mL, were included.
The study included 443 patients. The average time to achieve normalized TSH levels was 6.9 months. Key factors associated with delayed TSH normalization included higher body mass index (BMI) [odds ratio (OR) = 1.06, confidence interval (CI): 1.01-1.12], elevated serum free T4 levels (OR = 1.97; CI, 1.44-2.69), and treatment with propylthiouracil (OR = 2.66; CI, 1.33-5.32). In contrast, factors such as sex, age, season of diagnosis, and comorbidities did not significantly impact the rate of TSH normalization.
The study highlights the importance of considering individual patient characteristics, such as BMI and initial free T4 levels, in thyrotoxicosis management. The findings suggest a potential preference for carbimazole over PTU in achieving faster TSH normalization. This research contributes to the understanding of thyrotoxicosis recovery and supports the need for personalized treatment approaches in clinical practice.
了解甲状腺毒症患者恢复延迟的因素对于优化治疗方案至关重要。
本研究旨在确定甲状腺毒症患者甲状腺功能恢复延迟的预测因素。
本研究是对2014年1月至2021年12月在台湾高雄荣民总医院诊断的成年甲状腺毒症患者的病历进行回顾性研究。主要结局的随访时间至少为18个月。
纳入年龄>18岁、促甲状腺激素(TSH)水平<0.1 μIU/mL、接受卡马西平(CBZ)或丙硫氧嘧啶(PTU)治疗且随后TSH升高至0.4 μIU/mL以上的新诊断甲状腺毒症患者。
该研究纳入了443例患者。TSH水平恢复正常的平均时间为6.9个月。与TSH正常化延迟相关的关键因素包括较高的体重指数(BMI)[比值比(OR)=1.06,置信区间(CI):1.01-1.12]、血清游离T4水平升高(OR = 1.97;CI,1.44-2.69)以及丙硫氧嘧啶治疗(OR = 2.66;CI,1.33-5.32)。相比之下,性别、年龄、诊断季节和合并症等因素对TSH正常化率没有显著影响。
该研究强调了在甲状腺毒症管理中考虑个体患者特征(如BMI和初始游离T4水平)的重要性。研究结果表明,在实现更快的TSH正常化方面,卡比马唑可能比PTU更具优势。本研究有助于了解甲状腺毒症的恢复情况,并支持临床实践中个性化治疗方法的必要性。